People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

Lyn Iemma, aged 75 years at the time of writing, would not describe her life as dramatic. Born and raised in Perth, WA, Australia, this thriving but relaxed city is the place she has always called ...

The adjusted likelihood for an injurious fall in adults with COPD was elevated with a fall-risk increasing drug prescription, ...

The study reveals SGLT-2is are linked to fewer COPD exacerbations in type 2 diabetes, suggesting a need for further clinical ...

For patients with advanced emphysema, EBV is associated with higher mortality and morbidity compared with LVRS.

"This may inform prescribing of glucose-lowering medications among patients with T2D and active COPD," making SGLT2 and GLP-1 drugs preferable over DPP-4 inhibitors for these patients, the group ...

Sodium-glucose cotransporter 2, or SGLT2, inhibitors and glucagon-like peptide-1 receptor agonists lowered the risk for COPD exacerbation in adults with the disease and type 2 diabetes, researchers ...

The results of this comparative effectiveness research study suggest that sodium-glucose cotransporter-2 inhibitors  and glucagon-like peptide-1 receptor agonists (GLP-1RAs) were associated with a ...

People in rural areas are at greater risk of developing chronic obstructive pulmonary disease (COPD) due to a variety of factors. We explain why.

A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

Objective: To investigate the efficacy and tolerability of high-dose N-acetylcysteine (NAC) in the treatment of patients with exacerbations of chronic obstructive pulmonary disease (COPD).

Discover how UMass Memorial Medical Center's new North Pavilion facility is improving patient and caregiver experience while meeting community care needs.